Evidence map›Paper›PMID 41026851›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2025

Advanced cardiotoxicity profiling using field potential imaging with UHD-CMOS-MEA in human iPSC-derived cardiomyocytes.

Naoki Matsuda, Nami Nagafuku, Kazuki Matsuda, Yuto Ishibashi, Tomohiko Taniguchi, Yusaku Matsushita, Norimasa Miyamoto, Takashi Yoshinaga, Ikuro Suzuki

Abstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naoki MatsudaDepartment of Electronics, Graduate School of Engineering, Tohoku Institute of Technology, Sendai, Miyagi 982-8577, Japan.
Nami NagafukuDepartment of Electronics, Graduate School of Engineering, Tohoku Institute of Technology, Sendai, Miyagi 982-8577, Japan.
Kazuki MatsudaDepartment of Electronics, Graduate School of Engineering, Tohoku Institute of Technology, Sendai, Miyagi 982-8577, Japan.
Yuto IshibashiDepartment of Electronics, Graduate School of Engineering, Tohoku Institute of Technology, Sendai, Miyagi 982-8577, Japan.
Tomohiko TaniguchiAdvanced Biosignal Safety Assessment, Biopharmaceutical Assessments Unit, Tsukuba, Ibaraki 300-2635, Japan.
Yusaku MatsushitaAdvanced Biosignal Safety Assessment, Biopharmaceutical Assessments Unit, Tsukuba, Ibaraki 300-2635, Japan.
Norimasa MiyamotoAdvanced Biosignal Safety Assessment, Biopharmaceutical Assessments Unit, Tsukuba, Ibaraki 300-2635, Japan.ORCID 0000-0003-0391-1339
Takashi YoshinagaAdvanced Biosignal Safety Assessment, Biopharmaceutical Assessments Unit, Tsukuba, Ibaraki 300-2635, Japan.
Ikuro SuzukiDepartment of Electronics, Graduate School of Engineering, Tohoku Institute of Technology, Sendai, Miyagi 982-8577, Japan.

Funding

Sony Semiconductor Solutions Inc. and Japan Agency for Medical Research and Development 22be1004203h0001
6 · The paper itself

Abstract

Accurate assessment of cardiotoxicity using human induced pluripotent stem cell (iPSC)-derived cardiomyocytes is critical for ensuring drug safety during preclinical development. However, existing in vitro methodologies predominantly focus on QT interval prolongation and arrhythmia risk, often lacking the capacity to capture the complex interplay among multiple ion channels or to detect early manifestations of chronic cardiotoxicity-both of which are essential for evaluating long-term cardiac safety. Moreover, reliable prediction of pharmacological mechanisms of action remains a significant challenge. In this study, we employed field potential imaging utilizing an ultra-high-density complementary metal-oxide-semiconductor microelectrode array (MEA) comprising 236,880 electrodes distributed across a 5.9 × 5.5 mm active area. With 91.9% surface coverage by 11 μm electrodes spaced at 0.25 μm, the platform achieves near single-cell resolution across the entire cardiomyocyte monolayer. This system enabled the extraction of high-resolution electrophysiological endpoints, including the number and spatial variability of excitation origins, conduction velocity, and propagation area-thereby extending the analytical capabilities beyond those of conventional MEAs. Pharmacological testing revealed compound-specific alterations: Isoproterenol increased excitation origins, mexiletine reduced conduction velocity, and E-4031 diminished propagation area. Although these agents are well characterized, their effects were visualized with unprecedented spatiotemporal resolution, reflecting their underlying mechanisms of action. Multivariate analysis incorporating both conventional and novel endpoints enabled accurate classification of mechanisms under acute conditions. Furthermore, chronic cardiotoxicity induced by low-dose doxorubicin (0.03 μM) was sensitively detected within 24 h-earlier and at lower concentrations than previously reported-based on significant reductions in conduction velocity and propagation area. Collectively, these findings establish a high-resolution, mechanism-aware framework for in vitro cardiotoxicity profiling, offering improved predictive accuracy by capturing multi-ion channel interactions, spatial conduction abnormalities, and early signs of chronic dysfunction.

Indexed as

Induced Pluripotent Stem CellsMyocytes, CardiacAction PotentialsCardiotoxicityCells, CulturedDoxorubicinHumansMicroelectrodesSemiconductorsDoxorubicincardiotoxicitychronic cardiotoxicityfield potential imaginghuman iPSC-derived cardiomyocytesin vitro toxicity assessmentUHD-CMOS-MEA

Identifiers

PMID41026851
PMCPMC12646587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.